{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:42:29Z","timestamp":1786718549120,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijp.ijp_544_17","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T02:31:02Z","timestamp":1544754662000},"page":"273","source":"Crossref","is-referenced-by-count":17,"title":["A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence"],"prefix":"10.4103","volume":"50","author":[{"given":"ArupKumar","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PramodKumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.247536-1","first-page":"687","volume-title":"Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital","author":"Saini","year":"2015","journal-title":"Indian J Pharm Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0250-474X","issn-type":"print"},{"key":"key-10.4103\/0253-7613.247536-2","first-page":"390","volume-title":"Pediatric pharmacovigilance in an institute of national importance: Journey has just begun","author":"Sharma","year":"2017","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.247536-3","first-page":"79","volume-title":"Incidence of adverse drug reactions with commonly prescribed drugs in tertiary care teaching hospital in India","author":"Ahmad","year":"2011","journal-title":"Int J Pharm Sci"},{"key":"key-10.4103\/0253-7613.247536-4","unstructured":"Stewart BW, Paul Kleihues P. World Cancer Report. Lyon, France: International Agency Research on Cancer; 2003."},{"key":"key-10.4103\/0253-7613.247536-5","first-page":"117","volume-title":"Projections of the cost of cancer care in the United States: 2010-2020","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0253-7613.247536-6","unstructured":"Chabner BA. General principles of cancer chemotherapy. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill Inc.; 2011. p. 1667-75."},{"key":"key-10.4103\/0253-7613.247536-7","first-page":"2477","volume-title":"Medication safety in the ambulatory chemotherapy setting","author":"Gandhi","year":"2005","journal-title":"Cancer"},{"key":"key-10.4103\/0253-7613.247536-8","first-page":"91","volume-title":"An introduction to adverse drug reaction reporting system in different countries","author":"Rabbur","year":"2005","journal-title":"Int J Pharm Prac"},{"key":"key-10.4103\/0253-7613.247536-9","first-page":"E19","volume-title":"Effect of the first chemotherapy course on the quality of life of cancer patients in Turkey","author":"Turgay","year":"2008","journal-title":"Cancer Nurs"},{"key":"key-10.4103\/0253-7613.247536-10","first-page":"169","volume-title":"A survey on correlative symptoms and its influence on quality of life in breast cancer patients","author":"Ma","year":"2007","journal-title":"Chin J Evid Based Med"},{"key":"key-10.4103\/0253-7613.247536-11","unstructured":"ADR form PvPI. Available from: http:\/\/www.cdsco.nic.in\/writereaddata\/ADR%20form%20PvPI.pdf. [Last accessed on 2017 Mar 06]."},{"key":"key-10.4103\/0253-7613.247536-12","first-page":"138","volume-title":"Classification of drugs using the ATC system (Anatomic, therapeutic, chemical classification) and the latest changes","author":"Skrbo","year":"2004","journal-title":"Med Arh"},{"key":"key-10.4103\/0253-7613.247536-13","first-page":"152","volume-title":"Adverse drug reaction and causality assessment scales","author":"Zaki","year":"2011","journal-title":"Lung India","ISSN":"https:\/\/id.crossref.org\/issn\/0970-2113","issn-type":"print"},{"key":"key-10.4103\/0253-7613.247536-14","first-page":"2229","volume-title":"Preventability and severity assessment in reporting adverse drug reactions","author":"Hartwig","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"key-10.4103\/0253-7613.247536-15","first-page":"1088, 1091","volume-title":"Control charts to monitor rates of adverse drug reactions","author":"Schumock","year":"1995","journal-title":"Hosp Pharm"},{"key":"key-10.4103\/0253-7613.247536-16","unstructured":"Balmer CM, Valley AW, Iannucci A. Cancer treatment and chemotherapy. In: Pharmacotherapy: A Pathophysiologic Approach. 6th ed. USA: McGraw-Hill Companies; 2005. p. 2279."},{"key":"key-10.4103\/0253-7613.247536-17","first-page":"3012","volume-title":"The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs","author":"Niraula","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.247536-18","first-page":"374","volume-title":"Adverse drug reaction monitoring in India","author":"Kshirsagar","year":"1993","journal-title":"J Assoc Physicians India"},{"key":"key-10.4103\/0253-7613.247536-19","first-page":"20","volume-title":"International pharmacovigilance: Developing cooperation to meet the challenges of the 21st century","author":"Lumpkin","year":"2000","journal-title":"Pharmacol Toxicol"},{"key":"key-10.4103\/0253-7613.247536-20","unstructured":"Misra AK, Thaware P, Sutradhar S, Rapelliwar A, Varma SK. Pharmacovigilance: Barriers and challenges. Mintage J Pharm Med Sci 2013;2;35-6."},{"key":"key-10.4103\/0253-7613.247536-21","first-page":"343","volume-title":"Awareness among tertiary care doctors about pharmacovigilance programme of India: Do endocrinologists differ from others?","author":"Sharma","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/0253-7613.247536-22","first-page":"40","volume-title":"Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study","author":"Surendiran","year":"2010","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.247536-23","first-page":"187103","volume-title":"Sex differences in drug disposition","author":"Soldin","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"key-10.4103\/0253-7613.247536-24","first-page":"1285","volume-title":"Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation","author":"Astolfi","year":"2013","journal-title":"Oncol Rep"},{"key":"key-10.4103\/0253-7613.247536-25","first-page":"107","volume-title":"Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Eastern India","author":"Prasad","year":"2013","journal-title":"J Pharmacovigil"},{"key":"key-10.4103\/0253-7613.247536-26","first-page":"233","volume-title":"Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis","author":"Grunberg","year":"2007","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0253-7613.247536-27","unstructured":"Hanlon JT, Ruby CM, Artz M. Geriatrics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy a Pathophysiologic Approach. 5th ed. New York: McGraw-Hill Inc.; 2002. p. 79-89."},{"key":"key-10.4103\/0253-7613.247536-28","first-page":"509","volume-title":"Adverse drug reaction profile of microtubule-damaging antineoplastic drugs: A focused pharmacovigilance study in India","author":"Manohar","year":"2016","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.247536-29","first-page":"85","volume-title":"Global burden of cancer","author":"Ma","year":"2006","journal-title":"Yale J Biol Med"},{"key":"key-10.4103\/0253-7613.247536-30","first-page":"214","volume-title":"Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal","author":"Mallik","year":"2007","journal-title":"Pak J Pharm Sci"},{"key":"key-10.4103\/0253-7613.247536-31","first-page":"626","volume-title":"The ten most common adverse drug reactions (ADRs) in oncology patients: Do they matter to you?","author":"Lau","year":"2004","journal-title":"Support Care Cancer"},{"key":"key-10.4103\/0253-7613.247536-32","first-page":"61","volume-title":"Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital","author":"Wahlang","year":"2017","journal-title":"Ther Adv Drug Saf"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:36:29Z","timestamp":1786714589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_544_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"alternative-id":["247536"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_544_17","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}